You are here:

prasugrel (Efient)

Advice

Following a full submission

prasugrel (Efient) co-administered with aspirin is accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention. Use is restricted to patients who are eligible to receive the 10mg dose of prasugrel.

When compared to an alternative antiplatelet agent, prasugrel demonstrated a significant reduction in the incidence of ischaemic events, mainly non-fatal myocardial infarction, in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Prasugrel was, however, also associated with an increased risk of clinically significant bleeding events.

Alternative treatments are available at a lower drug acquisition cost.

Drug Details

Drug Name: prasugrel (Efient)
SMC Drug ID: 562/09
Manufacturer: Daiichi Sankyo UK Ltd
Indication: Prevention of atherothrombotic events in acute coronary syndrome
BNF Category:
Sub Category: 2.9 Antiplatelet drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 7 September 2009

Back